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Background and Purpose—To address the increasing need to counsel patients about treatment indications for unruptured 
intracranial aneurysms (UIA), we endeavored to develop a consensus on assessment of UIAs among a group of specialists 
from diverse fields involved in research and treatment of UIAs.
Methods—After composition of the research group, a Delphi consensus was initiated to identify and rate all features, which 
may be relevant to assess UIAs and their treatment by using ranking scales and analysis of inter-rater agreement (IRA) 
for each factor. IRA was categorized as very high, high, moderate, or low.
Results—Ultimately, 39 specialists from 4 specialties agreed (high or very high IRAs) on the following key factors for 
or against UIA treatment decisions: (1) patient age, life expectancy, and comorbid diseases; (2) previous subarachnoid 
hemorrhage from a different aneurysm, family history for UIA or subarachnoid hemorrhage, nicotine use; (3) UIA size, 
location, and lobulation; (4) UIA growth or de novo formation on serial imaging; (5) clinical symptoms (cranial nerve 
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Unruptured intracranial aneurysms (UIAs) have a preva-lence of 2% to 3% in the general population.1,2 UIAs 
often remain clinically asymptomatic for a long time or 
rupture, causing subarachnoid hemorrhage (SAH). Patients 
having SAH from a ruptured aneurysm have a poor progno-
sis with case-fatality rates up to 50%, which suggests that it 
could be beneficial to repair UIAs before they rupture.3 On the 
contrary, observational natural history studies of UIAs suggest 
that only a fraction of UIAs rupture, although these data are 
partially biased by selection of specific subgroups of UIAs.4,5 
Nevertheless results from long-term follow-up studies of 
UIAs with less selection of patients by aneurysm treatment 
are, in part, consistent with these observations.6 Aneurysm 
size is considered the major risk factor for UIA rupture and in 
many respects is what drives treatment decisions. However, it 
has been difficult to reconcile the low risk of rupture of small 
UIAs and the high proportion of small ruptured aneurysms in 
patients with SAH.5,7 The resulting uncertainty about the natu-
ral history of UIAs and their appropriate treatment has become 
important as more people undergo brain imaging for nonspe-
cific symptoms and are found to have incidental UIAs, which 
are usually small, that is, <7 mm in diameter.5,8,9 Overall, the 
rupture rate of aneurysms is on average 9/100 000 people per 
year.10 A limitation to making treatment decisions about UIAs 
is lack of consensus on factors that are associated with rupture 
of UIAs and that would allow for prediction of rupture. This 
limitation is compounded by generation of data that are not 
comparable between studies, and there is little clarity on what 
questions to ask in future studies. The goal of this work was 
to address these problems by convening a panel of special-
ists from diverse fields involved in research and treatment of 
UIAs. We used the Delphi consensus method to identify and 
rate all features thought necessary to assess and manage UIAs.
Methods
The goal of this project was to determine what highly informed in-
dividuals who study and treat UIAs considered to be relevant factors 
influencing their decisions about UIA management and to analyze the 
certainty within the group. The purpose of this process therefore was to 
establish consensus and was not to quantify the probable risk of rupture 
of UIAs or the treatment risk because there are already data on these 
questions that have been subjected to meta-analyses.4,5,11–15 To achieve 
our objective we used a Web-based survey (www.surveymonkey.com) 
and a 5-step Delphi consensus approach.16,17 Factors considered rel-
evant to evaluate and treat UIAs based on knowledge derived from a 
multidisciplinary and international panel of neurovascular specialists 
were identified and rated. In the first phase of this project, a panel of 
specialists (see below) was assembled. Two authors who did not par-
ticipate in the Delphi process then designed different survey rounds and 
analyzed the data in the second phase (N. Etminan and K. Beseoglu). 
In the first 4 rounds, panelists were blinded to their previous or their 
colleagues’ ratings to reduce the risk of bias within the research group.
Specialist Panel
Specialists who were known from previous collaborations or based 
on their scientific publication record to have expertise in the treat-
ment of cerebral UIAs and SAH were contacted about participation 
in the study.18 We also performed a literature search using the terms 
cerebral aneurysm, subarachnoid hemorrhage, or unruptured intracra-
nial aneurysms and identified and then contacted the senior authors 
of the top 40 articles, based on citations in the Web of Science. The 
panel was purposely designed to select prominent physicians from a 
variety of specialties (neurosurgery, neurology, neuroradiology, and 
epidemiology) and to represent different continents. Every specialist 
who agreed to participate was included. The key purpose of this panel 
was to reach and formulate a consensus based on the current clinical 
evidence and practice in UIA management.19
Delphi Process
The Delphi process is a scientific method typically used to systemati-
cally reach a consensus on a controversial or complex subject among 
a group of professionally and geographically dispersed specialists.20 
We used a modified Delphi approach, consisting of 5 rounds to iden-
tify and rate the most relevant features used to assess and manage 
UIAs16,17 (Figure):
•	 Pre-Delphi phase (recruitment of expert panel): In September 
2012, 40 specialists were contacted via e-mail and asked to par-
ticipate in the project. The recruitment phase was finished a 
week after the initial contact.
•	 Delphi Round 1a (identification of relevant items): By defi-
nition, the first round of the Delphi process consists of open-
ended questions to identify all factors relevant to the subject. 
Open-ended questions and a Web-based survey were used to 
ask panel members to submit all clinical, radiological, and 
therapeutic factors/variables they each considered relevant to 
the risk of rupture and for treatment of UIAs, based on cur-
rent evidence and practice. Participants also were asked to list 
any missing factors or items in the open questions for each cat-
egory. Every reply from Round 1 was used to generate a list of 
features/cofactors considered necessary to assess UIAs.
•	 Delphi Round 1b (definition of items): We identified that defini-
tions varied for some items (eg, hypertension or familial aneu-
rysms). The panel members were asked to pick one from different 
definitions for the most common items (see under Definitions).
•	 Delphi Round 2 (rating and prioritization of items): The sug-
gested items and additional items listed by panel members in 
round 1 were compiled and included for subsequent rating by 
every member. Panel members were asked to rate each feature 
listed in round 1 of the survey using a 0 to 10 scoring system, 
with 0 reflecting nonrelevance and 10 reflecting absolute im-
portance. To avoid bias, the results of round 2 were not pre-
sented to the panel until completion of round 3.
•	 Delphi Round 3 (rerating of all items from Round 2): To achieve a 
more robust consensus and to exclude significant deviations over 
time, panel members repeated the round 2 survey 4 weeks later.
deficit, mass effect, and thromboembolic events from UIAs); and (6) risk factors for UIA treatment (patient age and life 
expectancy, UIA size, and estimated risk of treatment). However, IRAs for features rated with low relevance were also 
generally low, which underlined the existing controversy about the natural history of UIAs.
Conclusions—Our results highlight that neurovascular specialists currently consider many features as important when 
evaluating UIAs but also highlight that the appreciation of natural history of UIAs remains uncertain, even within a group 
of highly informed individuals. (Stroke. 2014;45:1523-1530.)
Key Words: cerebral aneurysm ◼ consensus ◼ Delphi technique ◼ incidental aneurysm ◼ natural history  
◼ therapeutics
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•	 Delphi Round 4 (refining of items): Every item and the corre-
sponding relevance ratings were then presented to the panel to 
evaluate whether they might have been underrated or overrated.
•	 Delphi Round 5 (summary of findings and proposal): In the 
final round, the panel was presented the proposal and asked to 
approve or disprove the final consensus version.
Definitions
All nonsaccular aneurysms, that is, rare aneurysms associated with 
specific diseases/entities (eg, collagen disorders, dwarfism, Moya- 
Moya syndrome), and aneurysms in patients <18 years were excluded 
because they are rare, may have a distinct natural history, and would 
increase the complexity of the proposal. A complex aneurysm was 
defined as an aneurysm of any size that also has any of the follow-
ing features: wide neck, lobulations, calcifications, intra- aneurysm 
thrombus, proximal vessel tortuosity/stenosis, branch artery incorpo-
rated into the neck or aneurysm sac. Aneurysm size was defined as 
the greatest CA diameter, measured using 3-dimensional reconstruc-
tion of the catheter angiograms. Aneurysm lobulation was defined as 
irregular, daughter-sack–like protrusion of the aneurysm wall on the 
3-dimensional angiographic reconstruction images. Aspect ratio was 
defined as the ratio of aneurysm neck and aneurysm dome diameter. 
Size ratio was the largest aneurysm diameter divided through parent 
vessel diameter. Hypertension, irrespective of whether it was treated 
or untreated, was defined as systolic blood pressures >140 mm Hg 
and diastolic blood pressure >90 mm Hg.21 Current nicotine use was 
defined as a risk factor for adults who had smoked 100 cigarettes in 
their lifetime and smoked cigarettes every day (daily) or some days 
(nondaily) at the time of clinical presentation.22 Familial aneurysms 
were defined to be present in families where ≥2 first degree relatives 
were diagnosed with a UIA or SAH previously.23 Current drug use 
was defined as a risk factor in case of a recent cocaine or amphet-
amine exposure, that is, within 1 year of clinical presentation. Clinical 
or radiological signs of mass effect were defined as any symptoms or 
findings indicative of a space-occupying effect from an UIA, such as 
nausea, vomiting, focal neurological or radiological findings (midline 
shift and herniation, edema, cranial nerve compression). Cranial nerve 
deficits were defined as any deficits from compression of a cranial 
nerve, for example, visual disturbances, oculomotor dysfunction for 
anterior circulation, and lower cranial nerve deficits (IX, X, or XI) for 
posterior circulation aneurysms. Psychiatric disorders were defined 
as manifest clinical depression, bipolar affective disorder, schizoaf-
fective psychosis, or obsessive-compulsive disorders with resulting 
impairment of the patient’s ability to live alone. Neurocognitive 
disorders were defined as dementia, Alzheimer disease, frontotem-
poral neurocognitive disorder, and resulting impairment of the pa-
tient’s ability to live alone because of the neurocognitive disorder. 
Concomitant chronic or malignant disease were defined as any car-
diovascular-, pulmonary, -renal or gastrointestinal, musculoskeletal, 
and central nervous chronic or malignant disease that impaired the 
patient’s life expectancy. Concomitant thrombophilic diseases were 
defined as Factor-V Leiden mutation, antiphospholipid antibody 
syndrome, antithrombin III deficiency, and protein C/S deficiency. 
Concomitant coagulopathies were defined as hemophilia and von 
Willebrand disease. Concomitant use of anticoagulants was defined 
as concomitant treatment with warfarin, dabigatran, rivaroxaban, or 
apixaban in the presence of an UIA. Concomitant use of platelet in-
hibitors was defined as concomitant treatment of patients with aspirin 
or clopidogel in the presence of a UIA. Treatment was defined as 
neurosurgical clipping or endovascular repair of a UIA. Conservative 
management was defined as observation or medical treatment (eg, 
for epilepsy).
Statistical Analysis
Statistical analysis was performed using SPSS 15.0.1 (Ulead 
Technologies, Chicago, IL). Medians and interquartile ranges were 
determined for each item rated in rounds 2 and 3. Medians were cho-
sen over means to account for the small sample size and to avoid dis-
tortion by outliers and skewed distributions. To classify the relevance 
of each item to evaluate a UIA based on the panel ratings, 3 groups 
were established: high relevance (median 7–10), moderate relevance 
(median 4–6), and low relevance (median 0–3). Medians of ratings 
and interquartile ratios are presented.
The exploratory analysis of this project focused on intrarater agree-
ment, that is, variances in ratings between rounds 2 and 3 for each 
specialist and inter-rater agreement (IRA), that is, the homogeneity 
of ratings among the panel. Differences in individual ratings between 
rounds 2 and 3 were evaluated using the nonparametric Wilcoxon 
signed-rank tests for matched pairs. Significance was accepted at a 
level of P<0.05. The skew of the distribution of votes was determined 
as a measure of the direction of ratings in round 3. A negative skew 
(asymmetry in the distribution of votes) reflected the tendency for 
higher relevance, a positive skew for lower relevance. A skewness 
value that approached zero corresponded to a symmetrical distribu-
tion of votes.
The standardized quartile coefficients of dispersion (v
r
*) were 
calculated to determine the degree of inter-rater agreement for every 
item. In deciding the relevance of an item for the rating of each item 
according to v
Q Q
Q
n
r
*
=
−
−
3 1
2
1
 with 0 ≤ v
r
* ≤ 1, thus v
r
* approaching zero 
corresponds to a high degree of inter-rater agreement. The degree of 
agreement was classified using the calculation of quartiles of v
r
* as 
such (1) the lower quartile was defined as low IRA, (2) the second 
quartile as moderate IRA, (3) the third quartile as high IRA, and (4) 
the upper quartile as very high IRA.
Results
Thirty-nine out of the 40 contacted specialists from 12 coun-
tries and 4 continents agreed to participate in September 2012. 
The subspecialties and panel composition are illustrated in the 
Figure. For all rounds, the predefined minimum participation 
Figure. Illustration of the Delphi consensus approach to identify 
and rate all features considered relevant to assess and manage 
unruptured intracranial aneurysms.
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rate of 85% was fulfilled (87% in round 1, 97% in round 2, 
92% in round 3, 87% in round 4, and 100% in round 5; Figure). 
The panel proposed 60 features they considered necessary to 
assess and decide about management of a UIA in round 1. 
These were subsequently rated for their relevance in rounds 
2 and 3. In round 4, the research group reached consensus for 
all ratings from rounds 2 and 3 because the panel votes in this 
round did not reveal significant overrating or underrating of 
factors in this round. For analytic and illustrative purposes, 
the items were classified as patient, aneurysm, or treatment 
related. In the final round, all 39 panel members approved 
the proposal. The v
r
* ranges for the IRA classification were 
based on 1.000 to 0.160 for low (first quartile), 0.159 to 0.101 
for moderate (second quartile), 0.100 to 0.070 for high (third 
quartile), 0.069 to 0.000 for very high IRA (fourth quartile).
Patient-Related UIA Items
Twenty-eight patient-related items were listed in round 1 
(Table 1). The subsequent ratings in rounds 2 and 3 defined 
the following items that were considered highly relevant to 
support aneurysm treatment and that were generally indepen-
dent of other factors: (1) patient age <30 years, (2) familial 
intracranial aneurysms, (3) previous SAH from a different 
aneurysm, and (4) current nicotine consumption.
However, despite patient age <30 years being rated as 
highly relevant, IRA for this agreement was moderate. For 
the other age categories rated with moderate or low relevance, 
the IRAs were very high. Additionally, the only items rated 
highly relevant with high or very high IRA in favor of treat-
ment were familial intracranial aneurysms and current nico-
tine consumption.
Highly relevant patient-related aspects that independently 
supported conservative management of a UIA were (1) chronic 
or malignant diseases associated with a life expectancy <5 or 
5 to 10 years and (2) neurocognitive disorders. For both items 
inter-rater agreement on relevance was very high. The major-
ity of all other features in this category were either rated to be 
moderately relevant or irrelevant, with moderate to low IRAs.
Additionally, 7 items were proposed to lower the risk of 
rupture of UIAs, that is, as protective measures (Table 1). The 
most relevant modifiable items were blood pressure control 
and nicotine cessation. However, only nicotine cessation was 
rated with very high IRA. The remaining items were rated as 
moderately relevant or irrelevant, the majority of which exhib-
ited considerable ambiguity (low IRA).
Aneurysm-Related UIA Items
Twenty aneurysm-related items were listed in round 1 
(Table 2). Ratings in round 2 and 3 identified the following 
features considered important (high relevance) in support of 
treatment: (1) UIA size >13 mm, (2) UIA sac lobulation, (3) 
UIA location (anterior or posterior communicating artery or 
basilar artery bifurcation), (4) UIA growth or de novo forma-
tion, and (5) symptoms, such as cranial nerve deficits, mass 
effect, and thromboembolic events from the UIA. IRA for rat-
ing of these items was consistently high or very high, although 
there was moderate or low IRA related to the relevance of UIA 
<7 mm in diameter.
Treatment-Related UIA Items
Sixteen treatment-related items were listed (Table 3). The 
most relevant feature considered to increase treatment risk was 
aneurysm diameter >20 mm. A feature considered most rel-
evant to favor conservative management of a UIA was patient 
age >80 years or life expectancy <5 years. IRA among the 
panel members for these items was very high. The importance 
of individual patient factors to decide about treatment such 
as age, life expectancy, aneurysm size, and individual risk of 
treatment were generally rated with high or very high IRAs.
Discussion
The key findings of this study are that many factors are consid-
ered to be relevant to an appropriate assessment of UIAs rup-
ture risk by a group of specialists presumably knowledgeable 
on the natural history UIAs, and that the relative importance 
of factors rated as irrelevant is yet uncertain, as evident by low 
IRAs. The most relevant factors identified for UIA treatment 
decisions were (1) patient age, life expectancy, and comor-
bid diseases, (2) modifiable and nonmodifiable risk factors for 
aneurysm formation and rupture (previous SAH from a differ-
ent aneurysms, family history for intracranial aneurysms or 
SAH, nicotine consumption), (3) UIA size, location, and lobu-
lation, (4) UIA growth and de novo formation on serial imag-
ing, (5) clinical symptoms (cranial nerve deficit, mass effect, 
and thromboembolic events from the aneurysm), and (6) risk 
factors for UIA treatment (patient age and life expectancy, 
aneurysm size, and estimated individual risk of treatment).
The natural history of UIAs remains incompletely 
understood. The largest natural history studies include the 
International Study of Unruptured Intracranial Aneurysms 
(ISUIA) and the Study on the Natural Course of Unruptured 
Cerebral Aneurysms in a Japanese Cohort (UCAS Japan).4,5 
Both these studies reported low 5-year cumulative risks of 
rupture for anterior circulation aneurysms <7 mm in diameter. 
In UCAS Japan, greater rupture rates for UIAs of the anterior 
or posterior communicating artery and irregular shaped UIAs 
were reported compared with UIAs at different parent arteries 
or of regular shape. Despite some methodological concerns, 
such as selection bias, sample size, short observational peri-
ods, and ethnic/racial composition of the cohorts, these data 
show that only a fraction of UIAs rupture during a short obser-
vation period and that most of these are >7 mm in diameter. 
However, a high proportion of ruptured aneurysms are <7 
mm in diameter.7,24 To explain this discrepancy, it has been 
hypothesized that UIAs undergo episodes of instability and 
growth followed by periods of stabilization, with stochastic or 
discontinuous rather than linear growth.25,26 Therefore, short 
observation intervals may not accurately account for this.26,27 
However, until more knowledge is available, clinicians must 
rely on many factors, as outlined in Tables 1–3 to decide on 
the risk of treatment or rupture. Our proposal provides more 
guidance on the relevance of these features needed to assess 
UIAs, based on a consensus among a large, international and 
multidisciplinary group of neurovascular specialists.
Our results suggest that in addition to the most com-
monly acknowledged factors such as patient age, aneurysm 
size, and location, several other patient-, aneurysm-, and 
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Table 1. Patient-Related Factors
Median IQR Relevance Skew P Value
Change Between 
Rounds 2 and 3 vr* IRA
Importance of patient age in relation to UIA treatment
 Age <30 y 8 6.75 High −0.236 0.075 0.127 Moderate
 Age range 30–60 y 6 4 Moderate −0.277 0.972 0.048 Very high
 Age range 61–80 y 5 3 Moderate 0.160 0.075 0.042 Very high
 Age >80 y 2 3 Low 0.950 <0.001 Increase 0.038 Very high
Importance of risk factors supporting UIA treatment
 Previous SAH from a different aneurysm 9 3.75 High −0.883 0.158 0.085 High
 Family history for UIAs or SAH† 7 3.75 High −0.871 0.566 0.000 Very high
  Autosomal-dominant polycystic 
kidney disease
6 4.25 Moderate −0.351 0.433 0.141 Moderate
 Japanese, Finnish, or Innuit ethnicity 5 4 Moderate −0.404 0.902 0.101 Moderate
 Female sex 3 4 Low 0.393 0.343 0.225 Low
 Postmenopause phase 2 5 Low 0.984 0.233 0.296 Low
 Nicotine consumption (current) 8 3 High −0.969 0.380 0.056 Very high
 Hypertension (current)† 6 3 Moderate 0.051 0.764 0.085 High
 Drug abuse (current)† 5 5 Moderate −0.167 0.961 0.169 Low
 Alcohol abuse (current)† 4 3 Moderate 0.294 0.626 0.118 Moderate
  Contralateral stenoocclusive vessel  
disease
3 3 Low 0.286 0.317 0.169 Low
 Concomitant anticoagulants 2 3.75 Low 1.071 0.400 0.507 Low
 Concomitant platelet inhibitors 2 3 Low 1.157 0.184 0.282 Low
Importance of comorbid diseases supporting conservative management
  Chronic/malignant disease with life  
expectancy <5 y†
10 1 High −2.421 0.466 0.017 Very high
  Chronic/malignant disease with life  
expectancy 5–10 y†
7 3 High −0.989 0.668 0.072 High
  Chronic/malignant disease with life  
expectancy >10 y†
4 4 Moderate 0.401 0.347 0.148 Moderate
  Impaired QOL because of 
neurocognitive disorder†
8 3 High −0.590 0.366 0.068 Very high
 Psychiatric disorder† 5 4 Moderate 0.267 0.056 0.101 Moderate
 Coagulopathies† 5 4 Moderate 0.269 0.381 0.135 Moderate
 Thrombophilic diseases† 5 5 Moderate 0.382 0.189 0.101 Moderate
 Diabetes mellitus 2 2 Low 0.669 0.947 0.169 Low
Risk factor modification/protective factors
 Blood pressure control 8 4 High −0.674 0.686 0.106 Moderate
 Nicotine cessation 8 4 High −1.020 0.331 0.085 High
 Alcohol cessation 3 3 Low 0.278 0.136 0.169 Low
 Aspirin use 2 5 Low 0.858 0.934 0.423 Low
 Statin use 2 3 Low 0.959 0.775 0.254 Low
 Regular exercise 2 4 Low 0.699 0.326 0.338 Low
 Avoid rigorous physical activity 1 3 Low 0.676 0.118 0.592 Low
Other
  Patients’ reduced QOL because of fear 
from subsequent rupture of an UIA
5 4 Moderate 0.263 0.440 0.135 Moderate
Importance of all patient-related items in relation to treatment indications for unruptured intracranial aneurysms (UIAs) and corresponding inter-rater 
agreement (IRA). The P values indicate differences in ratings between rounds 2 and 3, that is, intrarater agreement. Skew indicates the directionality 
of ratings within round 3, with negative skew indicating the tendency for higher relevance and positive skew lower relevance corresponding to an 
asymmetry in the distribution of votes. IQR indicates interquartile ratio; QOL, quality of life; SAH, subarachnoid hemorrhage; and v
r*, standardized 
quartile coefficient of dispersion.
†See under Definitions.
 by SEPPO JUVELA on May 8, 2014http://stroke.ahajournals.org/Downloaded from 
1528  Stroke  May 2014
treatment- related factors contribute to decision making in 
the daily management of UIAs. However, despite attaining a 
consensus from a panel of neurovascular specialists for these 
factors and their ratings, our data illustrate that there is het-
erogeneity or uncertainty related to importance of individual 
features that are considered to influence whether or not to 
treat a UIA. Interestingly, this ambiguity was generally low 
for factors, which were rated as highly relevant and, more-
over, for ratings on the important factors associated with UIA 
treatment risk. Treatment of a UIA is a single and immediate 
event and thus more accurately estimable, which may explain 
high IRAs observed within the treatment category. Moreover, 
the existing knowledge on UIA treatment risks may be con-
sidered more representative and robust than those on the natu-
ral history of UIAs, especially for controversial UIA aspects, 
such as UIAs <7 mm or the importance of potential risk fac-
tors, such as alcohol use or concomitant use of anticoagulants 
or platelet inhibitors. Ultimately, our results underscore the 
need for a better understanding of the pathophysiology of 
aneurysm rupture, so that more appropriate radiological or 
other surrogates can be used to identify UIAs at increased 
risk of rupture.
There are several potential limitations of our study. First, 
the present data are derived from existing evidence and from 
personal opinions of specialists, that is, there may be bias. 
Additionally, the high proportion of surgical or radiological 
interventionists in our research group may or may not add 
to this bias because of a potentially higher tendency to treat 
UIAs, per se. Second, there was heterogeneity between ratings 
for some items, which emphasizes the existing uncertainty on 
Table 2. Aneurysm-Related Factors
Median IQR Relevance Skew P Value
Change Between 
Rounds 2 and 3 vr* IRA
Importance of aneurysm size supporting UIA treatment
 Aneurysm size >25 mm 10 0 High −4.282 0.722 0.000 Very high
 Aneurysm size 13–24 mm 8 2 High −0.463 0.967 0.047 Very high
 Aneurysm size 7–12 mm 6 2 Moderate 0.183 0.870 0.063 High
 Aneurysm size 4–6 mm 3 2 Low 0.463 0.904 0.126 Moderate
 Aneurysm size 1–3 mm 1 2 Low 0.209 0.439 0.378 Low
Importance of aneurysm morphology supporting UIA treatment
 Aneurysm lobulation 7 3 High −0.172 0.380 0.072 High
 Size ratio† 4 3 Moderate 0.313 0.542 0.148 Moderate
 Aspect ratio† 4 3 Moderate 0.181 0.431 0.127 Moderate
 Aneurysm sphericity 3 2 Low 0.269 0.527 0.113 Moderate
 Aneurysm ellipticity 3 3 Low 0.502 0.749 0.169 Low
Importance of aneurysm location supporting UIA treatment
 AComA and PcomA 7 3 High −0.380 0.589 0.085 High
 Basilar artery bifurcation 7 3 High −0.537 0.653 0.072 High
 Vertebral artery 5 3 Moderate 0.203 0.221 0.113 Moderate
Importance of radiological findings supporting UIA treatment
 Aneurysm growth on serial imaging 9 2 High −1.657 0.034 0.038 Very high
  De novo aneurysm formation on 
serial imaging
8 3.75 High −0.593 0.008 0.090 Very high
  Aneurysm location (parent 
vessel, per se)
6 3 Moderate 0.007 <0.001 Decrease 0.085 Very high
 Aneurysm multiplicity 4 3 Moderate 0.368 <0.001 Decrease 0.148 Moderate
Importance of clinical symptoms supporting UIA treatment
 Cranial nerve deficits† 9 2 High −1.488 0.558 0.038 Very high
  Clinical or radiological signs of mass 
effect because of aneurysm†
10 2 High −1.243 0.129 0.038 Very high
  Thromboembolic event from  
the aneurysm
7 3 High −0.263 0.002 Decrease 0.099 Very high
 Epilepsy 3 5 Low 0.424 0.391 0.310 Moderate
 Chronic headaches 1 2 Low 0.675 0.594 0.338 Low
Importance of all aneurysm-related items in relation to treatment indications for unruptured intracranial aneurysms (UIAs) and corresponding 
inter-rater agreement (IRA). The P values indicate differences in ratings between rounds 2 and 3, that is, intrarater agreement. Skew indicates 
the directionality of ratings within round 3, with negative skew indicating the tendency for higher relevance and positive skew lower relevance 
corresponding to an asymmetry in the distribution of votes. AComA indicates anterior communicating artery; IQR, interquartile ratio; PComA, posterior 
communicating artery; and v
r*, standardized quartile coefficient of dispersion.
†See under Definitions.
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the natural history of UIAs. However, these data highlight 
areas of uncertainty and are contributing to identification 
of potentially interesting focus for further research. Third, 
the definition of some features, such as aneurysm complex-
ity or categories for aneurysm size and patient age may be 
arbitrary. Although these definitions were applied consistently 
throughout the different Delphi rounds, reducing any poten-
tial bias, more precise and reproducible categorization is cur-
rently lacking. Fourth, we used different scales for aneurysm 
size and patient age to estimate the natural history of UIAs 
and their treatment because of the heterogeneous or limited 
prospective data on these subjects. Nevertheless, within our 
surveys, panel members were asked for the preferred catego-
ries for aneurysm size and patient age, and the majority of the 
panel (> 2/3) chose the ones used in this proposal.
Conclusions
Our results highlight that specialists in neurovascular dis-
ease consider many features to be important when evaluating 
UIAs. Importantly, our results also underline that the natu-
ral history of UIAs remains uncertain, which underlines the 
necessity for a more comprehensive understanding of UIA 
biology to address the increasing need to reliably counsel 
patients with UIAs.
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